Cybin prices $50M share offering to fund late-stage psychedelic trials
What's the deal? Cybin (Nasdaq: HELP) priced an underwritten offering of 10,309,280 common shares at $4.85 each, targeting $50 million in gross proceeds. CantorDealroom has a profile for this one. Try Dealroom → and BarclaysDealroom has a profile for this one. Try Dealroom → are joint bookrunning managers, with the offering expected to close June 25, 2026.
What's the endgame? Net proceeds will fund the Phase 3 trial of HLP003 for major depressive disorder, plus HLP004 for generalized anxiety disorder, HLP005, and general corporate purposes. Cybin develops psychedelic-based therapies targeting mental health conditions.
Why now? The raise lands ahead of a key milestone: Phase 3 data for HLP003 is expected in the fourth quarter of 2026. The fresh capital gives the company runway to reach that readout and advance its wider pipeline.
What could go wrong? Issuing more than 10 million new shares dilutes existing shareholders. The closing also remains subject to customary conditions and Cboe Canada approval.
The signal: Post-IPO equity raises like this are how clinical-stage drug developers bridge the gap to pivotal trial data. For Cybin, the $50 million is a bet that its lead candidate can clear late-stage testing — and the market rewarded the move, with shares gaining 4.95% on the day of the announcement.
Read more: StockTitan
Image credit: jurvetson
